Article Text

AB0679 One third of primary sjÖgren syndrome (PSS) patients with anti-CCP develop erosive rheumatoid arthritis (RA) after a 5-year follow-up
  1. J. Payet1,
  2. R. Seror1,
  3. J.-E. Gottenberg2,
  4. E. Berger1,
  5. F. Desmoulins1,
  6. O. Meyer3,
  7. X. Mariette1
  1. 1Université Paris Sud, Bicêtre Hospital, Le kremlin Bicêtre
  2. 2Hôpitaux universitaires de Strasbourg, Strasbourg
  3. 3Bichat Hospital, Paris, France


Background Rheumatologic manifestations affect 30 to 70% of pSS patients and present as recurrent and transient arthralgia or a real polyarthritis. These manifestations may sometimes be very similar to that of RA, but the presence of joint destruction and erosions is a specific hallmark of RA and help at distinguishing these 2 diseases. Anti-CCP antibodies are highly specific for the diagnosis of RA but were found in other systemic diseases. In pSS, their prevalence is about 5 to 10%.

Objectives To follow patients with pSS and anti-CCP during more than 5 years to establish frequency and predictors of evolution to RA.

Methods A retrospective, observational, multicentric study was performed including all patients having pSS and anti-CCP and having a follow-up of more than 5 years in 2 French rheumatology departments. At diagnosis, patients met AECG criteria for pSS diagnosis, but did not meet ACR 1987 criteria for the diagnosis of RA. At inclusion, collected data were: demographic; clinical data about articular manifestations, sicca syndrome and systemic involvement; immunological and radiological data. Hand and feet X-rays were systematically performed 5 years after inclusion. During follow-up, diagnosis of RA was done in case of appearance of bone erosions on foot or hand X-rays

Results In all, 16 patients were included in the study: 14 (87.5%) were women, median age was 52 (33 to 71) years, 10 (62.5%) patients had arthralgia and 7 (43.7%) had arthritis at diagnosis. Subjective xerostomia was present in 15 patients (93.7%) and subjective xerophtalmia in 14 patients (87.5%). Anti-SSA antibodies were found in 10 patients (62.5%) and anti-SSB in 6 patients (37.5%). After a median follow-up of 8 (5 to 10) years, 11 patients were still considered as having a pSS and 5 patients developed a real erosive RA. Anti-CCP persisted at 5 years in all patients but one in whom the initial anti-CCP level was 50 IU. In univariate analysis, predictors of evolution to RA were high ESR (p=0,037) and high CRP (p=0,033) at diagnosis. In multivariate analysis, only ESR was associated to an increased risk of developing erosive RA.

Conclusions Although it is established that 5-10% of pSS patients have anti-CCP, one-third of them might develop a true RA. A close monitoring of these patients seems necessary to look for erosive changes that indicate a pejorative evolution and might require more active treatment.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.